Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;1(2):95-107.
doi: 10.1177/1758834009338633.

Angiogenesis inhibitors in the treatment of non-small cell lung cancer

Joline S W Lind  1 , Egbert F Smit
Affiliations

Angiogenesis inhibitors in the treatment of non-small cell lung cancer

Joline S W Lind et al. Ther Adv Med Oncol. 2009 Sep.

Abstract

A therapeutic plateau seems to have been reached with the standard treatment of cytotoxic chemotherapy alone for advanced stage non-small cell lung cancer (NSCLC) and new treatment options are urgently needed. Recent insight into the molecular biology of cancer has identified angiogenesis as one of the key biological processes. The major player in tumor angiogenesis is the vascular endothelial growth factor (VEGF) pathway. VEGF is expressed in the majority of NSCLC and overexpression is associated with a poor prognosis. The VEGF pathway can be inhibited in two main ways: targeting VEGF directly or inhibiting the VEGF receptors. The development of angiogenesis inhibitors has shown great promise in the treatment of NSCLC. Bevacizumab, an anti-VEGF antibody, has been approved for the treatment of advanced NSCLC and other drugs are undergoing phase III investigation. However, a number of unresolved issues remain. In this review, we discuss the main angiogenesis inhibitors in development for the treatment of NSCLC focusing on the VEGF pathway.

Keywords: angiogenesis inhibitors; bevacizumab; non-small cell lung cancer; vascular endothelial growth factor.

PubMed Disclaimer

References

    1. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al. (2008) A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. J Clin Oncol (Meeting Abstracts) 26: 8080–8080
    1. Adjei A.A., Molina J.R., Mandrekar S.J., Marks R., Reid J.R., Croghan G., et al. (2007) Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13: 2684–2691 - PubMed
    1. Altorki N., Guarino M., Lee P., Pass H.I., Filip E., Bauer T., et al. (2008) Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. J Clin Oncol (Meeting Abstracts) 26: 7557–7557
    1. Beaudry P., Force J., Naumov G.N., Wang A., Baker C.H., Ryan A., et al. (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11: 3514–3522 - PubMed
    1. Blumenschein G., Jr,, Sandler A., O’Rourke T., Eschenberg M., Sun Y., Gladish G., et al. (2006) Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 24: 7119–7119